|Effectiveness of L-thyroxine treatment on TSH suppression during pregnancy in patients with a history of thyroid carcinoma after total thyroidectomy and radioiodine ablation.|
|Jump to Full Text|
|PMID: 23077453 Owner: NLM Status: PubMed-not-MEDLINE|
|INTRODUCTION: There are scarce data about the optimal increase of L-thyroxine dose during pregnancy in patients with a history of thyroid carcinoma. The first aim of the study was to find out if routine therapeutic measures enable adequate TSH suppression in pregnancy. The other aim was to find out the optimal dose of L-thyroxine for TSH suppression in pregnant women.
PATIENTS AND METHODS: In this retrospective observational study, we analysed 36 pregnancies of 32 women with a history of thyroid carcinoma. Before pregnancy, all of them underwent total thyroidectomy and radioiodine ablation of thyroid remnant, and they were on suppressive doses of L-thyroxine. Thyroid function tests were obtained before, during and after pregnancy.
RESULTS: Mean L-thyroxine dose before pregnancy, in the first, second and, third trimester and after delivery was 149, 147, 155, 165 and 158 micrograms daily, respectively. TSH concentration remained suppressed in 9 pregnancies, it was within normal range in 22 and elevated in 5 pregnancies. The mean dose of L-thyroxine in patients with suppressed TSH before pregnancy, in the first, second and, third trimester and after delivery was 154, 154, 164, 160 and 161 micrograms daily, respectively. When the dose had to be changed, the mean increase of the dose was 31.5 micrograms daily.
CONCLUSIONS: The range of changes in TSH concentration during pregnancy in the patients who have been on suppressive L-thyroxine therapy before conception is quite wide. TSH was adequately suppressed in only 25% of pregnancies. The dose of L-thyroxine in patients with suppressed TSH in the first, second and third trimester was 154, 164 and 160 micrograms daily, respectively.
|Blaz Krhin; Nikola Besic|
Related Documents :
|8416443 - Intrauterine device failure: relation to its location within the uterine cavity.
18330813 - The contraceptive efficacy of implanon: a review of clinical trials and marketing exper...
2107033 - Effects of brain microtubule-associated proteins on microtubule dynamics and the nuclea...
|Type: Journal Article Date: 2012-01-02|
|Title: Radiology and oncology Volume: 46 ISSN: 1581-3207 ISO Abbreviation: Radiol Oncol Publication Date: 2012 Jun|
|Created Date: 2012-10-18 Completed Date: 2012-10-19 Revised Date: 2013-06-21|
Medline Journal Info:
|Nlm Unique ID: 9317213 Medline TA: Radiol Oncol Country: Slovenia|
|Languages: eng Pagination: 160-5 Citation Subset: -|
|Department of Laboratory Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia.|
|APA/MLA Format Download EndNote Download BibTex|
Journal ID (nlm-ta): Radiol Oncol
Journal ID (iso-abbrev): Radiol Oncol
Journal ID (publisher-id): RADO
Publisher: Versita, Warsaw
Copyright © by Association of Radiology & Oncology
Received Day: 29 Month: 9 Year: 2011
Accepted Day: 24 Month: 11 Year: 2011
Electronic publication date: Day: 02 Month: 1 Year: 2012
collection publication date: Month: 6 Year: 2012
Volume: 46 Issue: 2
First Page: 160 Last Page: 165
PubMed Id: 23077453
Publisher Id: rado-46-02-160
|Effectiveness of L-thyroxine treatment on TSH suppression during pregnancy in patients with a history of thyroid carcinoma after total thyroidectomy and radioiodine ablation|
1 Department of Laboratory Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia
2 Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
|Correspondence: Correspondence to: Prof. Nikola Bešič MD, PhD, Dept. of Surgical Oncology, Institute of Oncology Ljubljana, Zaloška 2, SI-1000 Ljubljana, Slovenia. Phone: +386 1 5879 953; Fax:+386 1 5879400; E-mail: firstname.lastname@example.org
Disclosure: No potential conflicts of interest were disclosed.
Thyroid hormones are important for normal pregnancy and the foetal development.1,2 During pregnancy, maternal thyroid hormones requirements increase.3,4 It is well known that the reference values of TSH, free T3 and free T4 for healthy the non-pregnant population are not the same as during pregnancy. Dashe et al.5 published the data about the TSH concentration in 13,599 pregnancies. They found out that the normal physiological concentration of TSH during the first trimester of pregnancy was as low as 0.1 mU/L. According to the trimester-specific reference ranges of serum, TSH concentrations above 2.3 mU/L in the first trimester and 3.1–3.5 mU/L in the second and third trimester may already be indicative of subclinical hypothyroidism.1,6 Safety of pregnancy during subclinical hyperthyroidism was reported by Casey et al.7 They found out that the subclinical hyperthyroidism was not associated with the adverse outcome of pregnancy.7
The patients having undergone thyroidectomy and radioiodine therapy are dependent on exogenous L-thyroxine.8 Some authors advocate that the increase of dose of L-thyroxine during pregnancy should be determined from the results of thyroid function tests8–11, while others propose to increase L-thyroxine dose as soon as pregnancy is confirmed.12,13
There are very limited data in the literature about the changes of TSH and thyroid hormones during pregnancy in patients with a history of thyroid carcinoma. To our knowledge, these studies included only a small number of patients8, 12–15 with the largest study group of 18 such cases reported by Loh et al.8 There are scarce data about the optimal increase of L-thyroxine dose during pregnancy in the patients with thyroid carcinoma after total thyroidectomy and radioiodine ablation of thyroid remnant. The first aim of the study was to find out if routine therapeutic measures enable adequate TSH suppression in pregnancy. The other aim was to find out the optimal dose of L-thyroxine for TSH suppression in pregnant women.
In this retrospective observational study we analysed 36 pregnancies of 32 women (mean age at conception 29.9 ± 0.6 years) with a history of thyroid carcinoma during the period from 2000 to 2009. T1, T2 and T3 tumour was diagnosed in 15, 7 and 10 patients, respectively. In 23 and 9 patients, the tumour stage was assessed as N0 and N1, respectively. None of the patients had distant metastases. All of them had no evidence of disease at conception and after delivery. Histopathology of bioptic specimen revealed the presence of Hashimoto’s thyroiditis in 11/36 (=31%) of patients. Before pregnancy, all of them underwent total thyroidectomy and radioiodine ablation of the thyroid remnant and they were all on suppressive doses of L-thyroxine. All patients were advised to take L-thyroxine four hours before vitamins, iron or calcium drugs.
At conception, the age of patients was 22 to 37 years (mean age 29.9 ± 0.6 years). Among our patients, 28 women were pregnant once and four twice. Pregnancy passed without any events in 30 cases and with complications in six cases (premature delivery in two cases, preeclampsia in one, increased blood pressure in one, high serum glucose concentration in two, vaginal bleeding in the seventh month of gestation in one case).
Thyroid function tests were performed before, during and after pregnancy. The last test of thyroid function before pregnancy was done 1–12 (median 3) months before conception. During pregnancy, a clinical exam and thyroid function tests were performed every 6–8 weeks. When more than one set of tests was performed in any one trimester, the highest TSH concentration with the corresponding free T3 and free T4 concentrations were used in the statistical analysis in order to minimize any bias towards avoidance of dose change. The median number of thyroid function tests performed during pregnancy in each woman was four (range3–6). L-thyroxine dose was modified to maintain serum TSH below 0.3 mU/L. Suppression dose was adequate if TSH was 0.01–0.29 mU/L and free T3 was within normal range.
From 2000–2006, TSH was measured by the two-site immunoluminometric assay (sandwich principle) LIASON TSH (Byk-Sangtec Diagnostica, Dietzenbach, Germany). Free T3 and free T4 were measured by commercially available kits (LIAISON FT3, LIAISON FT4) with “LIAISON” Immunoassay System (Byk-Sangtec, Germany later DiaSorin, Italy). Reference values for TSH, free T3 and free T4 were 0.27–4.2 mU/L, 2.93–6.8 pmol/L and 7.7–23.2 pmol/L, respectively. From 2007 onwards, TSH, free T3 and free T4 were measured by commercially available kits (TSH, FT3, FT4) with “Modular Analytics E170” Immunoassay System (Roche Diagnostics, Mannheim, Germany). Reference values for TSH, free T3 and free T4 were 0.27–4.20 mIU/L, 3.1–6.8 pmol/L and 12–22 pmol/L, respectively.
The study was reviewed by the appropriate medical ethics committee. The Institute’s Protocol Review Board approved the study, which was performed in accordance with the medical ethics standards laid down in an appropriate version of the 1964 Declaration of Helsinki. The participants gave informed consent.
Changes in the results of thyroid-function tests, and L-thyroxine doses throughout pregnancy were analysed by repeated measures ANOVA or Friedman’s test, followed by Wilcoxon signed rank test in case of non-normal data distribution. P-values of less than 0.05 were considered to indicate statistical significance. The software package SPSS 16.0 for Windows (SPSS Inc., Chicago, IL USA) was used.
The mean concentration of TSH, freeT4 and free T3 before pregnancy, in the first, second and third trimester and after delivery are presented in Table 1. The concentration of TSH during the first, second and third trimester were higher in comparison to the TSH concentration before pregnancy (p<0.001). The changes of TSH concentration during pregnancy are presented in Figure 1. In none of our patients, a decrease of TSH was observed in the first 16 weeks of pregnancy.
The doses of L-thyroxine during the second and the third trimester were higher than the doses before pregnancy (p<0.05). The changes of dose of L-thyroxine during pregnancy are presented in Figure 2. Obese patients had larger dose of L-thyroxine in comparison to patients with normal body mass index (BMI) or underweight patients before conception as well as during pregnancy. However, BMI had no impact on the proportion of patients with adequate TSH suppression during pregnancy. The time period from the last test before pregnancy to the first test in pregnancy did not differ in women with adequate TSH suppression and women with inadequate TSH suppression (p=0.377).
Changes of the mean TSH concentration and dose of L-thyroxine before and during pregnancy and after delivery in patients with suppressed and not suppressed TSH concentration are presented in Table 2. The mean dose of L-thyroxine in patients with suppressed TSH before pregnancy, in the first, second and, third trimester and after delivery was 154, 154, 164, 160 and 161 micrograms daily, respectively.
In 36 pregnancies, the TSH concentration remained suppressed during 9 pregnancies. In 22 pregnancies the TSH concentration was within normal range,whilein5 pregnancies it was elevated. A dose of L-thyroxine was not changed in 14 pregnancies (mean dose 159 micrograms daily); TSH was suppressed in 5 pregnancies and within normal range in 9 pregnancies.
The dose of L-thyroxine had to be increased in 22 pregnancies. The TSH concentration in 22 pregnancies remained suppressed in 4, within normal range in 13 and elevated in 5 of them. TSH was over 5.0 mU/L during the first trimester and second trimester in 5/22 (23%) cases and 3/22 (14%) cases, respectively.
The dose of L-thyroxine was increased 30 times and decreased four times during the course of pregnancy. The dose was changed 9, 11 and 14 times in the second, third and the fifth month, respectively. The mean increase of L-thyroxine dose in these 22 cases was 32.15 (range 25–75) micrograms.
According to the current American Thyroid Association and European Thyroid Association guidelines16,17, the patients with a history of thyroid carcinoma are either on substitution or suppressive doses of L-thyroxine. Our study group consisted of 36 pregnancies in 32 patients with a history of thyroid carcinoma. Before conception they were treated by total thyroidectomy and radioiodine ablation of thyroid remnant and were on the suppressive dose of L-thyroxine. So, in all of our patients there was no viable thyroid tissue to produce thyroid hormones. These patients were, therefore, entirely dependent on exogenous L-thyroxine.
In healthy women, a transient decrement of serum TSH concentration occurs during the first two months of pregnancy, which is a result of the elevation of human chorionic gonadotropin (hCG) having similar molecular structure as TSH.1,18,19 In none of our patients, lower concentration of TSH was detected during the first two months of pregnancy. In the absence of viable thyroid tissue, there was no effect of elevated concentration of hCG on the synthesis and secretion of thyroid hormones from thyroid and on the consequent decrease of TSH concentration.
According to Endocrine Society Clinical Practice Guideline1, L-thyroxine dose often needs to be increased within 4–6 weeks of gestation and may require a 30–50% addition of dosage.3,4 But we observed that there was no need to increase the dose during pregnancy in 25% of our cases who were on suppressive doses of L-thyroxine before conception. Also Loh et al.8 observed that there was no need to change the dosage in some of the patients with thyroid carcinoma who were on TSH suppression therapy before pregnancy. Based on our results, we believe that an increment of dose immediately after conception as advocated by some authors12 is not appropriate for all the patients who are on suppressive doses of L-thyroxine. We agree with Loh at al.8 that these patients may be over treated by an empiric increase of L-thyroxine dose and may develop overt hyperthyroidism.
The other important finding of our study is that TSH suppression was not achieved in 75% of cases when thyroid testing was performed each 6–8 weeks. Furthermore, an elevation of TSH level above normal was observed in 14% of our patients. Possibly, this could be avoided, if thyroid function tests would be obtained every 4–6 weeks as recommended by Endocrine Society Clinical Practice Guideline1, or every 4 weeks as recommended by Yassa et al..13 In a recent study Yassa et al.13 performed serum testing every two weeks until the 20th week of pregnancy and at the 30th week of pregnancy. If blood samples were obtained every four weeks, 92% of abnormal TSH concentrations were detected. But, if an every six week testing protocol had been followed, only 73% of abnormal TSH concentrations would have been detected.10 So, they concluded that the thyroid function tests should be repeated every four weeks during the first half of pregnancy.
It is still not known when it is most appropriate to increase the dose of L-thyroxine20: before pregnancy21, immediately after conception12,13 or when elevation of TSH is observed.8–11 Rotondi et al.21 suggested the increase of L-thyroxine dose to “partially suppressive” dose before pregnancy. The patients who underwent thyroidectomy because of multinodular goitre or Hashimoto’s thyroiditis and who were on substitution therapy were randomized in two groups before conception: one group continued with substitution doses, while the other was on partially suppressive dose.21 Before conception, the average dose in the substitution group and the partially suppressive group of patients was 143 and 178 micrograms, while the average TSH was 1.84 and 0.48 (0.32–0.7) mU/L, respectively.21 TSH level above 3.5 mU/L was found to be more common in the substitution group in comparison to the “partially suppressive” group of patients (36% vs. 14%).
Another approach, i.e. increment of the dose as soon as pregnancy is confirmed, was proposed by Alexander et al..12 They studied precisely the timing and amount of L-thyroxine adjustment in 20 pregnancies in 19 women.12 Eight patients had Hashimoto’s disease, six thyroid carcinoma, three Graves disease and two were after the treatment for benign thyroid nodule. L-thyroxine requirements increased as early as the fifth week of gestation.12 That is why they recommended an increase of L-thyroxine dose as soon as possible.12 Their opinion is that the dose should be increased by about 30%.12 Yassa et al.13 performed a prospectively randomized study in which women were receiving an increased L-thyroxine dose at the beginning of pregnancy. The dose in the first group was increased by 29%, and in the second group, by 43%. The mean dose before and after the change in the first and the second group was 112, 145, 109 and 156 micrograms, respectively.13 After the change of dose, TSH suppression was present in 32% of women from the first group and in 65% of women from the second group; but less than 0.1 mU/L of TSH was found in only one patient (8%) from the first group and in six patients from the second group (26%).13 They found out that a 29% incr ease of dose (from 112 to 145 micrograms) prevented maternal TSH elevation over 2.5 and 5.0 mU/L in 85% and 100% of patients, respectively. But the majority of their patients had Hashimoto’s disease, while our patients had a history of thyroid carcinoma and were without any functional thyroid tissue. In our patients, the mean dose before pregnancy was 149 micrograms of L-thyroxine. When a dosage during pregnancy remained the same, the mean dose was 159 micrograms. This dosage prevented the elevation of TSH over 5.0 mU/L in all the cases. On the other hand, when a dosage during pregnancy had to be changed, the mean dose before conception was 125 micrograms only. In the latter cases, TSH was over 5.0 mU/L during the first and second trimester in 23% of cases and 14%, respectively.
The third approach, increment of a dose based on thyroid function tests was reported by Loh et al..8 In 18 cases with a history of thyroid carcinoma, the average daily L-thyroxine dose before conception was 153 micrograms. During pregnancy they required an increase of dose by 26%.8 In our patients, the average dose was 149 micrograms before conception. But during pregnancy our patients required an increase of dose by 11% only. Obviously the range of changes in TSH concentration during pregnancy in the patients who have been on suppressive L-thyroxine therapy before conception is quite wide.
As a conclusion, the patients with thyroid carcinoma who are on high doses of L-thyroxine require close monitoring of thyroid function tests during pregnancy. TSH was adequately suppressed in only 25% of pregnancies. The dose of L-thyroxine in patients with suppressed TSH in the first, second and third trimester was 154, 164 and 160 micrograms daily, respectively. When the dose had to be changed, the mean increase of the dose was 31.5 (range 25–75) micrograms daily.
Research studies P3-0289 supported by the Ministry of Education, Science and Sport of Slovenia. This work was presented in part at the 14th International Thyroid Congress, held in Paris, France, September 11–16 2011.
|1.||Abalovich M,Amino N,Barbour LA,Cobin RH,De Groot LJ,Glinoer D,et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice GuidelineJ Clin Endocrinol MetabYear: 200792S14717948378|
|2.||Haddow JE,Palomaki GE,Allan WC,Williams JR,Knight GJ,Gagnon J,et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the childN Engl J MedYear: 19993415495510451459|
|3.||Kaplan MM. Monitoring thyroxine treatment during pregnancyThyroidYear: 19922147521525583|
|4.||Mandel SJ,Larsen PR,Seely EW,Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidismN Engl J MedYear: 19903239162359428|
|5.||Dashe JS,Casey BM,Wells CE,McIntire DD,Byrd EW,Leveno KJ,et al. Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference rangesObstet GynecolYear: 2005106753716199632|
|6.||Panesar NS,Li CY,Rogers MS. Reference intervals for thyroid hormones in pregnant Chinese womenAnn Clin BiochemYear: 2001383293211471873|
|7.||Casey BM,Dashe JS,Wells CE,McIntire DD,Leveno KJ,Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomesObstet GynecolYear: 20061073374116449121|
|8.||Loh JA,Wartofsky L,Jonklaas J,Burman KD. The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidismThyroidYear: 2009192697519265498|
|9.||Girling JC,de Swiet M. Thyroxine dosage during pregnancy in women with primary hypothyroidismBr J Obstet GynaecolYear: 199299368701622906|
|10.||Verga U,Bergamaschi S,Cortelazzi D,Ronzoni S,Marconi AM,Beck-Peccoz P. Adjustment of L-T4 substitutive therapy in pregnant women with sub-clinical, overt or post-ablative hypothyroidismClin Endocrinol (Oxf)Year: 20097079880218771569|
|11.||Hallengren B,Lantz M,Andreasson B,Grennert L. Pregnant women on thyroxine substitution are often dysregulated in early pregnancyThyroidYear: 200919391419207005|
|12.||Alexander EK,Marqusee E,Lawrence J,Jarolim P,Fischer GA,Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidismN Engl J MedYear: 2004351241915254282|
|13.||Yassa L,Marqusee E,Fawcett R,Alexander EK. Thyroid hormone early adjustment in pregnancy (the THERAPY) trialJ Clin Endocrinol MetabYear: 20109532344120463094|
|14.||Chopra IJ,Baber K. Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine dose requirement in pregnancy?MetabolismYear: 200352122812524672|
|15.||Dobrenic M,Huic D,Zuvic M,Grosev D,Petrovic R,Samardzic T. Usefulness of low iodine diet in managing patients with differentiated thyroid cancer - initial resultsRadiol OncolYear: 2011451899522933955|
|16.||Cooper DS,Doherty GM,Haugen BR,Kloos RT,Lee SL,Mandel SJ,et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroidYear: 20061610914216420177|
|17.||Pacini F,Schlumberger M,Dralle H,Elisei R,Smit JW,Wiersinga W. The European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEurop J EndocrinolYear: 2006154787803|
|18.||Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathologyEndocr RevYear: 199718404339183570|
|19.||Gaberscek S,Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after deliveryExpert Rev Clin ImmunolYear: 2011769770721895480|
|20.||Toft A. Increased levothyroxine requirements in pregnancy--why, when, and how much?N Engl J MedYear: 2004351292415254288|
|21.||Rotondi M,Mazziotti G,Sorvillo F,Piscopo M,Cioffi M,Amato G,et al. Effects of increased thyroxine dosage pre-conception on thyroid function during early pregnancyEur J EndocrinolYear: 200415169570015588235|
Keywords: pregnancy, TSH suppression, L-thyroxine, thyroid carcinoma.
Previous Document: The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice.
Next Document: What sampling device is the most appropriate for vaginal vault cytology in gynaecological cancer fol...